Vanguard Group Inc. Purchases 11,967 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Vanguard Group Inc. boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 0.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,439,388 shares of the company’s stock after acquiring an additional 11,967 shares during the period. Vanguard Group Inc. owned 5.35% of Castle Biosciences worth $24,311,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CSTL. BluePath Capital Management LLC bought a new stake in Castle Biosciences in the 3rd quarter valued at about $31,000. Royal Bank of Canada increased its position in shares of Castle Biosciences by 40.5% during the second quarter. Royal Bank of Canada now owns 2,880 shares of the company’s stock valued at $39,000 after buying an additional 830 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Castle Biosciences by 61.2% during the third quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after buying an additional 691 shares during the period. Osaic Holdings Inc. increased its position in shares of Castle Biosciences by 37.2% during the second quarter. Osaic Holdings Inc. now owns 3,626 shares of the company’s stock valued at $50,000 after buying an additional 984 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in shares of Castle Biosciences during the first quarter valued at about $57,000. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CSTL has been the topic of several analyst reports. KeyCorp upped their price target on Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Scotiabank upped their price target on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research report on Friday, March 1st.

Insiders Place Their Bets

In other Castle Biosciences news, Director Daniel Bradbury sold 2,074 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $23.20, for a total value of $48,116.80. Following the completion of the sale, the director now owns 33,870 shares of the company’s stock, valued at $785,784. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Castle Biosciences news, insider Derek J. Maetzold sold 4,131 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $21.41, for a total value of $88,444.71. Following the completion of the sale, the insider now owns 74,473 shares of the company’s stock, valued at $1,594,466.93. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel Bradbury sold 2,074 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total value of $48,116.80. Following the sale, the director now directly owns 33,870 shares of the company’s stock, valued at approximately $785,784. The disclosure for this sale can be found here. Insiders sold a total of 48,115 shares of company stock valued at $1,011,443 over the last quarter. 7.70% of the stock is owned by corporate insiders.

Castle Biosciences Trading Down 3.5 %

Shares of NASDAQ CSTL opened at $20.06 on Friday. Castle Biosciences, Inc. has a 12 month low of $9.26 and a 12 month high of $26.70. The firm has a market capitalization of $550.65 million, a price-to-earnings ratio of -9.29 and a beta of 0.93. The business has a 50-day moving average of $21.99 and a 200-day moving average of $19.78.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. The company had revenue of $66.12 million during the quarter, compared to analyst estimates of $51.32 million. On average, analysts predict that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.